N-Acetylcysteine for the Treatment of Psychiatric Disorders: A Review of Current Evidence
Open accessThe DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Abstract
N-acetylcysteine, a sulphur-containing amino acid for the treatment of paracetamol overdose and chronic obstructive pulmonary disease, is a widely available off-the-shelf oral antioxidant supplement in many countries. With the potential to modulate several neurological pathways, including glutamate dysregulation, oxidative stress, and inflammation that can be beneficial to the brain functions, N-acetylcysteine is being explored as an adjunctive therapy for many psychiatric conditions. This narrative review synthesises and presents the current evidence from systematic reviews, meta-analyses, and latest clinical trials on N-acetylcysteine for addiction and substance abuse, schizophrenia, obsessive-compulsive and related disorders, and mood disorders. Good evidence exists to support the use of N-acetylcysteine as an adjunct treatment to reduce the total and negative symptoms of schizophrenia. N-acetylcysteine also appears to be effective in reducing craving in substance use disorders, especially for the treatment of cocaine and cannabis use among young people, in addition to preventing relapse in already abstinent individuals. Effects of N-acetylcysteine on obsessive-compulsive and related disorders, as well as on mood disorders, remain unclear with mixed reviews, even though promising evidence does exist. Larger and better-designed studies are required to further investigate the clinical effectiveness of N-acetylcysteine in these areas. Oral N-acetylcysteine is safe and well tolerated without any considerable adverse effects. Current evidence supports its use as an adjunctive therapy clinically for psychiatric conditions, administered concomitantly with existing medications, with a recommended dosage between 2000 and 2400 mg/day.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Carr, C. P., Martins, C. M. S., Stingel, A. M., Lemgruber, V. B., & Juruena, M. F. (2013) · Journal of Nervous & Mental Disease · doi:10.1097/nmd.0000000000000049 · Cited by 802
Berk, M., Copolov, D., Dean, O., Lu, K., Jeavons, S., Schapkaitz, I., Anderson-Hunt, M., Judd, F., Katz, F., Katz, P., et al. (2008) · Biological Psychiatry · doi:10.1016/j.biopsych.2008.03.004 · Cited by 552 · cited 2×
“[38] N-acetylcysteine was used as an adjunctive treatment with the participants continued their maintenance antipsychotic medication throughout the study.[38]”
MethodClinical trials of N-acetylcysteine in psychiatry and neurology: A systematic review
Deepmala, Slattery, J., Kumar, N., Delhey, L., Berk, M., Dean, O., Spielholz, C., & Frye, R. (2015) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2015.04.015 · Cited by 463
Jakobsen, J. C., Katakam, K. K., Schou, A., Hellmuth, S. G., Stallknecht, S. E., Leth-Møller, K., Iversen, M., Banke, M. B., Petersen, I. J., Klingenberg, S. L., et al. (2017) · BMC Psychiatry · doi:10.1186/s12888-016-1173-2 · Cited by 366
Glutamatergic Dysfunction in OCD
Chakrabarty, K., Bhattacharyya, S., Christopher, R., & Khanna, S. (2005) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300733 · Cited by 344 · cited 2×
“System Xc- exchanges extracellular glutamate for intracellular cysteine on a 1:1 ratio, promoting the activation of mGlu2/3 receptors and inhibiting presynaptic release of glutamate.[12, 13] Reduced expression of the system Xc- and GLT1 is associated with higher levels of synaptic glutamate transmission, decreased ton…”
BackgroundCabungcal, J.-H., Steullet, P., Kraftsik, R., Cuenod, M., & Do, K. Q. (2013) · Biological Psychiatry · doi:10.1016/j.biopsych.2012.09.020 · Cited by 232
Berk, M., Dean, O., Cotton, S. M., Gama, C. S., Kapczinski, F., Fernandes, B. S., Kohlmann, K., Jeavons, S., Hewitt, K., Allwang, C., et al. (2011) · Journal of Affective Disorders · doi:10.1016/j.jad.2011.06.005 · Cited by 181
Berk, M., Dean, O. M., Cotton, S. M., Jeavons, S., Tanious, M., Kohlmann, K., Hewitt, K., Moss, K., Allwang, C., Schapkaitz, I., et al. (2014) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.13m08454 · Cited by 172
A randomized placebo-controlled trial of N-acetylcysteine for cannabis use disorder in adults.
Gray, K. M., Sonne, S. C., McClure, E. A., Ghitza, U. E., Matthews, A. G., McRae-Clark, A. L., Carroll, K. M., Potter, J. S., Wiest, K., Mooney, L. J., et al. (2017) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2017.04.020 · Cited by 157 · cited 2×
“[9] Glutamate, in particular, is strongly implicated in the development and maintenance of conditions including obsessive-compulsive disorders and addiction.[10, 11] N-acetylcysteine regulates glutamate via the cysteineglutamate antiporter (system Xc-) and glial glutamate transporter (GLT1), both essential components…”
BackgroundOliver, G., Dean, O., Camfield, D., Blair-West, S., Ng, C., Berk, M., & Sarris, J. (2015) · Clinical Psychopharmacology and Neuroscience · doi:10.9758/cpn.2015.13.1.12 · Cited by 96
Cited by
Niu, B., Liao, K., Zhou, Y., Wen, T., Quan, G., Pan, X., & Wu, C. (2021) · Biomaterials · doi:10.1016/j.biomaterials.2021.121110 · Cited by 1,168
N-Acetylcysteine (NAC): Impacts on Human Health
Tenório, M. C. D. S., Graciliano, N. G., Moura, F. A., Oliveira, A. C. M. D., & Goulart, M. O. F. (2021) · Antioxidants · doi:10.3390/antiox10060967 · Cited by 526
“In some countries, including the United States, Canada, and Australia, NAC is commonly available as an over-the-counter nutritional supplement, with antioxidant properties and great commercial appeal as a nutraceutical [2].”
BackgroundOverview on the Effects of N-Acetylcysteine in Neurodegenerative Diseases
Tardiolo, G., Bramanti, P., & Mazzon, E. (2018) · Molecules · doi:10.3390/molecules23123305 · Cited by 285
Neuroinflammation as an etiological trigger for depression comorbid with inflammatory bowel disease
Craig, C. F., Filippone, R. T., Stavely, R., Bornstein, J. C., Apostolopoulos, V., & Nurgali, K. (2022) · Journal of Neuroinflammation · doi:10.1186/s12974-021-02354-1 · Cited by 124
Liu, Y., Chen, Z., Li, B., Yao, H., Zarka, M., Welch, J., Sachdev, P., Bridge, W., & Braidy, N. (2021) · Neurochemistry International · doi:10.1016/j.neuint.2020.104931 · Cited by 69
Oxidative and Nitrosative stress in major depressive disorder: a case control study
Somani, A., Singh, A. K., Gupta, B., Nagarkoti, S., Dalal, P. K., & Dikshit, M. (2022) · Brain Sciences · doi:10.3390/brainsci12020144 · Cited by 54
Nery, F. G., Li, W., DelBello, M. P., & Welge, J. A. (2021) · Bipolar Disorders · doi:10.1111/bdi.13039 · Cited by 29
Sarris, J., Byrne, G., Castle, D., Bousman, C., Oliver, G., Cribb, L., Blair-West, S., Brakoulias, V., Camfield, D., Ee, C., et al. (2022) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2022.110550 · Cited by 19
Metadata
- Authors
- Ooi, S. L., Green, R., & Pak, S. C.
- Venue
- BioMed Research International
- Publisher
- Wiley
- Published
- 2018-10-22
- Volume
- 2018
- Pages
- 1-8
- ISSN
- 1110-7243 (ISSN-L)
- 2314-6133
- 2314-6141
- OpenAlex
- W2895897802
- Cited by
- 98
- References
- 12
- FWCI
- 7.46
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.